SCTPF Stock UPDATES Stem Cell Therapeuti (SCTPF) 0.2669 08/21/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Stem Cell Therapeuti (SCTPF) 0.2669 $SCTPF

Trillium Therapeutics Expands CD47 Program Into Solid Tumors Through a Broad Academic Collaboration
Marketwire - Thu Aug 07, 6:04AM CDT
Trillium Therapeutics Inc. ("Trillium" (TSX: TR)(OTCQX: SCTPF), an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has entered into a collaboration with academic investigators in London, Ontario to explore the therapeutic potential of SIRPaFc, its CD47-blocking agent, in a variety of solid tumor models. The research will be conducted in the laboratories of Drs. James Koropatnick and Ting-Yim Lee, at the Lawson Health Research Institute and the Robarts Research Institute, University of Western Ontario. Trillium's funding will be matched 1:1 by a grant from the Ontario Research Fund - Research Excellence (ORF-RE), providing the collaboration with a robust research budget nearing $600,000.

Trillium Therapeutics Receives Prestigious National Award
Marketwire - Fri Jun 13, 9:01AM CDT
Trillium Therapeutics Inc. ("TTI" (TSX: TR)(OTCQX: SCTPF), an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has been awarded BIOTECanada's 2014 Gold Leaf Award as Early Stage Health Company of the Year.

Stem Cell Therapeutics Strengthens its Board of Directors
Marketwire - Mon Mar 10, 6:01AM CDT
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, today announced that Mr. Luke Beshar and Dr. Thomas Reynolds have been appointed to the Company's Board of Directors.

Stem Cell Therapeutics Announces Appointment of Dr. Calvin R. Stiller as Chairman
Marketwire - Thu Jan 30, 6:38AM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, is pleased to announce that its Board of Directors has elected Dr. Calvin R. Stiller as Chairman of the Board. Dr. Stiller has been a member of the Board since July 2011 and served as Lead Director and Chair of the Governance and Nominating Committee.

Stem Cell Therapeutics Announces Resignation of Director
Marketwire - Mon Jan 27, 6:01AM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, announces that effective today, Mr. David Allan has resigned from its board of directors.

Stem Cell Therapeutics Provides Corporate Update
Marketwire - Mon Jan 13, 6:01AM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, today provided the following six-month corporate update:

Stem Cell Therapeutics Appoints Dr. Robert Kirkman to Its Board of Directors
Marketwire - Tue Dec 17, 6:01AM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, today announced that industry veteran Dr. Robert L. Kirkman has been appointed to the Company's Board of Directors.

Stem Cell Therapeutics Completes $33 Million Private Placement
Marketwire - Fri Dec 13, 3:50PM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell- related therapeutics, is pleased to announce that it has raised gross proceeds of $33 million through a private placement of units. The financing proceeds will be used to advance the Company's CD47 cancer stem cell program through IND-enabling studies, manufacturing and phase 1 clinical trials.

Stem Cell Therapeutics Adopts Shareholder Rights Plan
Marketwire - Tue Sep 17, 6:01AM CDT
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), a biopharmaceutical company developing cancer stem cell-related therapeutics, today announces that it has adopted a shareholder rights plan (the "Plan" effective September 16, 2013. The Company will be seeking shareholder approval of the Plan at its next annual general and special meeting of shareholders.

Stem Cell Therapeutics Advances CD47 Antagonist Program Into IND-Enabling Phase
Marketwire - Mon Sep 09, 6:01AM CDT
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), a biopharmaceutical company developing cancer stem cell- related therapeutics, today announced that it has advanced its CD47 antagonist program into an Investigational New Drug (IND) enabling phase. In collaboration with a contract manufacturing organization, Stem Cell Therapeutics (SCT) will begin the manufacturing process to generate drug for formal toxicology studies and a subsequent phase I clinical study, which is anticipated to begin in H2/2015.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

HiTHIUM Joins Cambridge to Boost Global Energy Storage

Updated Category News Views 392

HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 139

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 255

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 253

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 204

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
LaserAway Expands to 244 Clinics Over 20 Years

Updated Category News Views 203

A Milestone in Aesthetic Dermatology Twenty years, folks. That's a long haul for most businesses, let alone one in the fickle field of aesthetic dermatology. LaserAway, the juggernaut in this arena, has just opened its 244th clinic at 6300 Kingery Hwy in Willowbrook, IL. Nothing to be sneezed at. Imagine running a business, let alone one that's been amping up aesthetic...

Continue Reading
Layne's Chicken Fingers Expands with Brownsville Opening

Updated Category News Views 200

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 122

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 281

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 166

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading

Top 5 Most Recently Viewed Articles

AngioDynamics' NanoKnife® System Receives FDA Clearance

Updated Category News Views 191

Introduction to AngioDynamics' Innovation AngioDynamics, Inc. (NASDAQ: ANGO), a forward-thinking medical technology firm, has made significant strides in restoring healthy blood flow and enhancing cancer treatment options. Recently, the company announced its accomplishment in receiving FDA 510(k) clearance for its advanced NanoKnife System, specifically designed for...

Continue Reading
Analyst Predicts iPhone Dominance in Apple's Future Revenues

Updated Category News Views 197

Apple's Revenue Outlook and iPhone Influence A recent analysis by Needham paints a promising picture for Apple Inc (NASDAQ: AAPL) as the company prepares for fiscal year 2025. Analyst Laura Martin affirmed a buy rating for Apple, setting an impressive price target of $260. This forecast is based on a well-crafted Discounted Cash Flow (DCF) model, which includes a cash tax...

Continue Reading
Sitetracker's Record Growth and Vision for Future Success

Updated Category News Views 398

Remarkable Achievements in 2024 for Sitetracker Sitetracker has reached significant milestones marking the close of its fiscal year with outstanding growth and exciting plans for the upcoming year. As a leader in the field of asset lifecycle management, they have positioned themselves strongly in markets worldwide, focusing on providing tools for various critical...

Continue Reading
Olympus Showcases Innovative ENT Solutions at Major Meetings

Updated Category News Views 176

Olympus Highlights Cutting-Edge ENT Solutions Olympus Corporation of the Americas, a leading medical technology company committed to enhancing health and safety, will unveil its extensive ENT portfolio at upcoming annual physician meetings. Attendees will have the opportunity to see how Olympus integrates hybrid endoscopy with advanced imaging and content management...

Continue Reading
Exciting Launch of Tech Mahindra Chess League Season 3

Updated Category News Views 101

Tech Mahindra Global Chess League Season 3 Launches with Excitement The Global Chess League (GCL) has officially begun its Season 3, and excitement fills the air as six teams are set to compete in 34 matches for the coveted championship trophy. The league kicked off at Mumbai's Royal Opera House, a perfect venue for this grand event. Spectacular Opening Ceremony in Mumbai...

Continue Reading